CSI Market
Sign In | Register

Fortress Biotech Inc (FBIO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access FBIO quarterly Cash Flow →
From Fortress Biotech Inc through Dec 31 2021, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-32.92
Depreciation & amortization0.40
Amortization of Other Assets5.66
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed-0.21
Increase (Decrease) in Inventories4.81
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation28.74
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Noncash Interest-
Noncash Interest Related Parties-
Contribution Of Services By Stockholder-
Change In Fair Value Of Common Stock Warrant Liability-
Change In Fair Value Of Embedded Conversion Feature-
Change In Preferred Stock Warrant Liability-
Change In Fair Value Of Short Term Investments-
Change In Fair Value Of Subsidiary Convertible Note-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Noncash Or Part Noncash Acquisition Payables Assumed-
Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed-
Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed-
Amortization Of Forgivable Loans To Registered Representatives-
Amortization Of Deferred Clearing Credit-
Issuance Of Common Stock For Pik Interest Expense-
Unpaid Debt Offering Cost-
Issue Of Common Stock For Acquiring License Value-
Debt Conversion Original Debt Amount-
Liabilities Assumed-
Issuance Of Common Stock For License Expenses-
Allowance For Doubtful Accounts Receivable Recoveries-
Income taxes-0.58
Trading Securities, Change in Unrealized Holding Gain (Loss)0.00
Accounts Receivable-19.33
Increase (Decrease) in Accounts Payable and Accrued Liabilities-7.97
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.55
Other Working Capital-1.35
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-44.59
Discontinued operations0.00
Net Cash flow from Operating Activities-65.78
Investing Activities
Capital Expenditures0.00
Sale of Capital Items1.17
Short-term Investments Proceeds0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Payment Of Deposit For Facility Build Out-
Payment To Deposit For Leasehold Improvement-
Payment For Research And Development Licenses-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Proceeds from Other Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Proceeds from Divestiture of Interest in Consolidated Subsidiaries0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested8.96
Accounts payable0.00
Proceeds from Collection of Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities10.12
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.63
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.66
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Payments for Mortgage Deposits0.00
Other financing activities net0.00
Other net75.08
Proceeds From Notes Payable Related Parties-
Payment For Notes Payable Related Party-
Proceeds From Notes Payable To Related Parties-
Payment Of Costs Related To Issuance Of Common Stock-
Issuance Of Convertible Preferred Stock Series B For Purchase Of Assets-
Payments Of Idb Notes Issuance Costs-
Transfer Of Restricted Cash-
Payment Of Notes Payable Asset Purchase Agreement-
Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan-
Proceeds From Issuance Of At Market Offering-
Payment Of Nsc Note-
Payment Of Subordinated Short Term Debt Issuance Costs-
Payment Of Debt Issuance Costs Associated With Subsidiary Convertible Notes-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid-0.66
Net Cash Flow from Financing Activities77.44
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-64.61
Total Cash Flow21.79
4 historic quarters locked

Sign in to unlock the full Fortress Biotech Inc cash flow history.

Sign In Create Free Account

About Fortress Biotech Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-037874

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License